Abstract:Non-small cell lung cancer (NSCLC) remains one of the deadliest cancers with metastatic disease being the primary driver of mortality. Therefore, there is a critical need for therapies that prevent disease dissemination in both early and late-stage disease presentations. Among the recent novel therapeutic combinations that have transformed the treatment landscape of NSCLC is an approach developed in our lab and others utilizing DNA methyltransferase inhibition (DNMTi) paired with histone deacetylase inhibition (HDACi) to sensitize patients to immunotherapy. However, most patients do not benefit durably from epigenetic therapy alone or in combination with other therapies. In this study, we identified STAT3 as an actionable target in tumor cells that synergizes with epigenetic therapy (DNMTi+HDACi). We and others have previously shown that STAT3 signaling is augmented after epigenetic therapy. To interrogate the importance of this finding, we treated a panel of 12 human NSCLC cell lines with STAT3i+epigenetic therapy and identified five cell lines demonstrating a synergistic reduction of cell viability. These in vitro monolayer observations were recapitulated in an intermediate complexity 3D model, thus providing orthogonal validation of response applicability in a more treatment-resistant setting. In addition to phenotypic characterization, we deployed RNA sequencing to define the whole transcriptome consequences of our novel therapeutic paradigm. These transcriptional data showed that STAT3i+epigenetic therapy suppressed cell cycle and activated apoptotic pathways, which were validated by immunoblotting and flow cytometry-based approaches. We further demonstrated a significant and durable reduction in colony formation after treatment with STAT3i+epigenetic therapy. Additionally, we observed significant perturbation of a subset of genes involved in both epithelial-to-mesenchymal transition and suppression of glutamine and fatty acid metabolism. Reliance on glutamine is considered a hallmark of cancer metabolism. Furthermore, glutamine metabolism has been implicated in the plasticity between epithelial and mesenchymal cancer cell states, which is required for metastatic success. Additionally, survival of metastatic cells requires upregulation of pathways that promote anchorage-independent growth and anoikis resistance, which are suppressed in our phenotypic and transcriptional data, respectively. Taken together, our results suggest 1. STAT3i+epigenetic therapy diminishes the ability of NSCLC cells to survive and return to a colony-forming state and 2. This phenotype is associated with metabolic dysfunction. Our studies therefore provide a basis for the development of novel strategies to intercept metastatic recolonization by impairing circulating tumor cells from seeding distant sites. Citation Format: Julia An, Ying-Yu Chen, Jina Park, Stephen Baylin, Michael Topper. STAT3 inhibition synergizes with epigenetic therapy to suppress glutamine metabolism and clonogenic potential in non-small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 3219.

The STAT3-MYC Axis Promotes Survival of Leukemia Stem Cells by Regulating SLC1A5 and Oxidative Phosphorylation

STAT3 modulates mitochondrial function and plays a critical role in the survival of leukemic stem cells

Expression and Functions of the STAT3-SCLIP Pathway in Chronic Myeloid Leukemia Cells.

Metabolic alterations mediated by STAT3 promotes drug persistence in CML

Simultaneous inhibition of Sirtuin 3 and cholesterol homeostasis targets acute myeloid leukemia stem cells by perturbing fatty acid β-oxidation and inducing lipotoxicity

STAT3 in acute myeloid leukemia facilitates natural killer cell-mediated surveillance

Targeting Molecular Signaling Pathways and Cytokine Responses to Modulate c-MYC in Acute Myeloid Leukemia

SIRT3 deacetylase activity confers chemoresistance in AML via regulation of mitochondrial oxidative phosphorylation.

Role of CXCR 4 / STAT 3 Pathway in Mesenchymal Stromal Cell-Mediated Drug Resistance of Acute Leukemia Cells

Autophagy inhibition impairs leukemia stem cell function in FLT3-ITD AML but has antagonistic interactions with tyrosine kinase inhibition

Targeting Metabolic Dependencies Fueling the TCA Cycle to Circumvent Therapy Resistance in Acute Myeloid Leukemia

STAT activation status differentiates leukemogenic from non-leukemogenic stem cells in AML and is suppressed by arsenic in t(6;9)-positive AML

Sp1 and c-Myc modulate drug resistance of leukemia stem cells by regulating survivin expression through the ERK-MSK MAPK signaling pathway

PI3Kγ maintains the self-renewal of acute myeloid leukemia stem cells by regulating the pentose phosphate pathway

ATF3 coordinates serine and nucleotide metabolism to drive cell cycle progression in acute myeloid leukemia

STAT5 promotes PD-L1 expression by facilitating histone lactylation to drive immunosuppression in acute myeloid leukemia

Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells

Sirt3 Sumoylation Contributes To Chemoresistance In Aml

Endothelial Lipase Promotes Acute Myeloid Leukemia Progression Through Metabolic Reprogramming

Abstract 3219: STAT3 inhibition synergizes with epigenetic therapy to suppress glutamine metabolism and clonogenic potential in non-small cell lung cancer

High Mitophagy and Low Glycolysis Predict Better Clinical Outcomes in Acute Myeloid Leukemias